Sara Reardon, Nature News, 22 June 2016 http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-us-panel-1.20137
An NIH advisory board has approved the use of CRISPR gene editing in a small scale cancer therapy trial. Eighteen patients with various cancers will have their T cells removed and edited using CRISPR before reintroduction. The T-cells will be edited to detect and destroy cancer cells effectively using the patients own immune system to treat cancer. This will not be the first use of edited T-cells to target disease. Previously zinc finger proteins had been used to edit T-cells in HIV patients and TALENS have been used to edit T-cells in cancer therapies. The use of CRISPR technology is an important step forward as the CRISPR/Cas system could be easily adapted to treat a variety of diseases.